Home > Insider Trading > Filing (0001209191-10-044427)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
901219	Human Genome Sciences Inc	HGSI	In Vitro & In Vivo Diagnostic Substances (2835)	223178468

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1332456	Barry Labinger	14200 Shady Grove Road Rockville MD 20850	Exec Vp & Cco	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2010-08-26	13,050	$4.92	13,050	No	4	M	Direct
Common Stock	Disposition	2010-08-26	13,050	$28.53	0	No	4	S	Direct
Common Stock	Acquisiton	2010-08-27	16,079	$4.92	16,079	No	4	M	Direct
Common Stock	Disposition	2010-08-27	16,079	$28.50	0	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Employee Stock Option - Right to Buy	Disposition	2010-08-26	13,050	$0.00	13,050	$4.92
Common Stock	Employee Stock Option - Right to Buy	Disposition	2010-08-27	16,079	$0.00	16,079	$4.92

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
136,950		2018-03-10	No	4	M	Direct
120,871		2018-03-10	No	4	M	Direct

Footnotes

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person and Charles Schwab effective 6/16/10.
This transaction was executed in multiple trades at prices ranging from $28.50 to $28.54. The price reported above reflects the weighted average sales price. Upon written request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price is available.
This transaction was executed in multiple trades at prices ranging from $28.50 to $28.51. The price reported above reflects the weighted average sales price. Upon written request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price is available.
One-eigth of the 150,000 options granted on March 10, 2008, vested on the six-month anniversary date (September, 2008) and the remaining options granted vested and continue to vest monthly on a ratable basis for the next 42 months commencing on October 10, 2008.